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Abstract
The role of virtual ligand screening in modern drug discovery is to mine large chemical collections and to prioritize for
experimental testing a comparatively small and diverse set of compounds with expected activity against a target. Several
studies have pointed out that the performance of virtual ligand screening can be improved by taking into account receptor
flexibility. Here, we systematically assess how multiple crystallographic receptor conformations, a powerful way of discretely
representing protein plasticity, can be exploited in screening protocols to separate binders from non-binders. Our analyses
encompass 36 targets of pharmaceutical relevance and are based on actual molecules with reported activity against those
targets. The results suggest that an ensemble receptor-based protocol displays a stronger discriminating power between
active and inactive molecules as compared to its standard single rigid receptor counterpart. Moreover, such a protocol can
be engineered not only to enrich a higher number of active compounds, but also to enhance their chemical diversity.
Finally, some clear indications can be gathered on how to select a subset of receptor conformations that is most likely to
provide the best performance in a real life scenario.
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Introduction
For over 20 years, High-Throughput Screening (HTS) has been
one of the leading hit identification strategies in drug discovery [1].
Despite recent technological advances, HTS is still very expensive in
terms of infrastructure, consumables, and personnel [2], being
mainly carried out at the industrial level. Furthermore, HTS has a
relatively high rate of false positives and false negatives, and is
limited to comparatively small screening libraries. In this regard,
Virtual Ligand Screening (VLS) represents a fast and cost-effective
alternative, in which much larger libraries are screened by
computational means [3,4]. Compounds are assigned a predicted
activity profile and are ranked accordingly. Experimental tests can
be limited to the topmost ranking fraction of the compounds where,
if the predictions are correct, the majority of active molecules will
have been placed. VLS protocols can also be devised to improve
‘‘early recognition’’, namely to increase the number of active
compounds that are prioritized for testing [5], and to catch the
broadest possible chemical diversity. Strategies to achieve these
improvements may vary depending on the in silico approach to VLS.
Usually, when a high quality crystallographic structure of the target
(or its homologue) is available, structure-based strategies represent a
suitable alternative to ligand- and pharmacophore-based methods
[6]. Compound libraries are screened by iterating standard docking
procedures against a target of interest, and the estimated binding
score is used to prioritize putative hits. Processing massive libraries
in a reasonable amount of time requires the introduction of several
simplifications [7–9] and approximations [10,11], which sometimes
lead to low-accuracy predictions [12–14]. The use of a single
receptor conformation is one of the major limitations that can
hamper the quality of results [15]. This is particularly detrimental
for early recognition since active compounds will act as true binders
only in the presence of the right receptor conformation [16,17].
Recently, many different implementations have been proposed
to take into account protein flexibility in molecular docking and
screening [18]. Multiple Receptor Conformations (MRC) is a
straightforward and intuitive way to discretely mimic target
plasticity [19]. In MRC docking, also known as ensemble docking,
each putative ligand is docked separately at each receptor
conformation, and the poses obtained in the independent runs
are merged together. The predicted bound pose is assumed to be
the one providing the overall best score. Several groups have
extended the idea of MRC docking to VLS to increase, through
receptor flexibility, the number of retrieved active molecules. The
MRC paradigm can be applied to experimentally solved
structures, computationally generated conformers, or both [20].
Remarkably, most of the studies only included multiple crystallo-
graphic structures. In these cases, protein plasticity could be directly
inferred and no further validation was required. For instance, a
seminal paper by Knegtel and coworkers reported attempts to
increase the enrichment of known binders by using several
crystallographic structures for both HIV protease and ras p21
[21]. For the HIV protease inhibitors, MRC docking systematically
outperformed single conformer runs. In the case of ras p21, MRC
docking performed better than the average, but it was outperformed
several times by certain specific receptor conformations. Interest-
ingly, the authors pointed out that, in a real (non-retrospective)
screening campaign, there is no way to tell in advance which
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conformers are going to provide an optimal separation. Other
studies have reported similar results when analyzing different
systems and employing different docking engines [22–26]. In
particular, Cavasotto and Abagyan have demonstrated how a
limited receptor flexibility can more greatly affect the score
determination (and thus the early recognition) than the reproduction
of ligand-protein x-ray complexes [27]. Barril and Morley carried
out a detailed analysis on the role of binding pocket flexibility in
ligand docking [28]. They observed that an ensemble consisting of
two conformations was enough to improve the enrichments in the
topmost 1% fraction. The addition of further conformations did not
significantly improve the performance and could even deteriorate it.
Finally, Craig and coworkers tested the efficacy of MRC docking
using BACE1 and cAbl with a challenging and purposely compiled
benchmark [29]. Interestingly, their results were analyzed in terms
of both enrichment and chemical diversity. In this context, we also
carried out studies on MRC, focusing on the protocol’s ability to
reproduce ligands’ x-ray poses, and taking into account induced fit
effects. We first used a specific but highly challenging structural set
[30,31], and then a more comprehensive benchmark [32]. This
latter set was further exploited to devise some practical rules for
identifying optimal receptor conformation subsets [33].
Here, the beneficial role of x-ray MRC in VLS campaigns is
explored systematically, carrying out retrospective screening
studies against 36 well-known pharmacological targets. To
improve accuracy, a set of drug-like ligands, compiled indepen-
dently from the receptors, was carefully selected. The results are
reported according to 5 robust figures of merit and evaluated by
means of the following criteria: i) the separation power (binders
from non-binders) as a function of receptor conformations; ii) the
MRC-VLS performance compared to single conformation
protocols (SRC-VLS) in terms of both number of active molecules
and their chemical diversity; iii) contribution of each single
receptor conformation to the MRC-VLS overall performance.
Materials and Methods
Benchmark Composition
The benchmark was obtained by selecting multiple high quality
crystallographic structures for 36 pharmaceutically relevant targets
from the Directory of Useful Decoys (DUD) [34,35]. In the release
adopted here, the original DUD set was filtered and annotated to
avoid an artificial enrichment due to chemical redundancy. The
crystal structures of targets were selected according to the criteria
outlined to compile the previously reported experimental section of
the flexible Pocketome and the 4D docking dataset [32,36]. In the
present study, the ability to provide a near-native pose for the
cognate ligand was excluded from the filtering criteria. Four targets
from DUD were excluded from the selection: HIV-1 Integrase
(UniProt: P35963 – POL_HV1BR) and Peroxisome Proliferator-
Activated Receptor c Ligand Binding Domain (UniProt: P37231 –
PPARG_HUMAN) due to the low number of ligands that were
included in the adopted release of DUD, Human S-Adenosyl
Homocysteine Hydrolase (UniProt: P23526 – SAHH_HUMAN)
and b-type Platelet-derived Growth Factor Receptor (UniProt:
P09619 – PGFRB_HUMAN) due to the lack of multiple high
quality crystallographic structures available.
Preparation of Receptor Structures
The correct atom types were assigned according to a modified
version of ECEPP/3 force field [37]. Hydrogen atoms and missing
heavy atoms were added. Zero occupancy side chains were
optimized and assigned the lowest energy conformation. Tauto-
meric states of Histidines and the positions of Asparagine and
Glutamine side chain amidic groups were optimized to improve
the hydrogen bond pattern. Polar hydrogen atoms were also
optimized. We deleted water molecules together with chains,
heteroatoms, and prosthetic groups not involved in the binding site
definition. The cognate ligands were deleted from the complexes
only after hydrogen optimization.
Preparation of Ligand Structures
3D atomic coordinates, tautomeric forms, stereochemistry,
hydrogen atoms, and protonation states were assigned to ligands
according to DUD. Each ligand was assigned MMFF force field
atom types and charges [38].
Binding Pocket Definition
The boundaries of the binding box were assumed to be known
and directly derived from co-crystallized ligand coordinates. To
achieve a common definition of the binding pocket, the receptor
structures were superimposed using backbone atoms within 3.5 A˚
from the ligands. The iterative superimposition algorithm adopted
here assigns different weights to different atomic subsets, gradually
approaching the best solution for aligning the template and the
other structures [39]. All residues with at least one side chain
heavy atom in the range of 3.5 A˚ from any of the ligands
belonging to the same ensemble were considered part of a
common definition of the binding pocket. In this way, binding
pocket could be defined consistently across the same structural
ensemble, varying in conformation but not in composition.
Single Conformer VLS
A standard screening run was carried out independently on each
target conformer (single receptor conformation procedure or SRC).
The docking engine used was the Biased Probability Monte Carlo
(BPMC) stochastic optimizer as implemented in ICM (Molsoft LLC,
La Jolla) [40–42]. The ligand binding site at the receptor was
represented by pre-calculated 0.5 A˚ spacing potential grid maps,
representing van der Waals potentials for hydrogens and heavy-
atoms, electrostatics, hydrophobicity, and hydrogen bonding,
respectively. The van der Waals interactions were described by
the 6–12 Lennard-Jones potential. However, since the 6–12
standard implementation is extremely sensitive to even small
deviations in atomic coordinates and can generate a large amount
of noise in the intermolecular energy calculations, the default ICM
docking procedure implements a smoother form of the Lennard-
Jones potential, capping the repulsive contribution to 4 kcal/mol. A
distance-dependent dielectric function was used (dielectric constant
set equal to 4.0). Given the number of rotatable bonds in the ligand,
the basic number of BPMC steps to be carried out was calculated by
an adaptive algorithm [39]. The binding energy was assessed with
the standard ICM empirical scoring function [40–44].
Combining Results from Individual Runs
Several combinations of the results of the individual runs were
probed to identify the most effective one in discerning actual binders
from decoys. Results from independent runs were merged in one list
and then re-ranked according to a descriptor inherited from
individual runs. This post-processing step was carried out by means
of ICM tables, data structures that allow storing, sorting, duplicates
removal, and, in general, database-like handling of docking results.
Re-ranking according to the best score (MRC-score) was a
straightforward procedure: individual scores were merged into
one list, which was then sorted in ascending order. In the unlikely
case that two molecules achieved exactly the same score, the
molecule displaying lower molecular weight achieved a better rank.
MRCs in Virtual Ligand Screening
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As an alternative, we used the combination obtained by re-ranking
all ligands according to the best rank that each compound obtained
across individual runs (MRC-rank). This procedure is not univocal
(there are possibly n molecules ranking first if n runs are carried out)
and therefore the list was processed again so that molecules with the
same best rank were then sorted according to their score.
Figures of Merit
The literature contained several metrics for evaluating the
effectiveness of a docking run in discriminating actual binders from
decoys, some of them addressing the issue of the early recognition
[5]. For evaluating the performance of different combinations of
protein conformers, we considered: the Area Under the Accumu-
lation Curve (AUAC), the area under the Receiver Operating
Characteristic curve (ROC), the Enrichment Factor (EF) [45] at
different thresholds, the Robust Initial Enhancement (RIE) [46],
and the Boltzmann-Enhanced Discrimination of ROC metric
(BEDROC) [5]. RIE as well as BEDROC needed the assignment
of a parameter, termed alpha, for which we chose a value of 20, as
suggested by the literature [5,46].
All 5 metrics rely on the so-called accumulation curve, Fa(k), where
the subscript ‘‘a’’ stands for active molecule, which represents the
count, possibly normalized, of how many true binders obtained a
rank better or equal to a given one in a docking run; Fa(k) contains
all the information needed to assess the performance of a run, and
a combination of multiple runs as well.
The AUAC is the area under the chart of Fa(k) and, in its discretized
version, takes the following expression:
1
nN
XN{1
k~0
Fa(k)zFa(kz1)½ ,
where n is the number of actual binders and N the total number of
screened molecules. It ranges from
n
2N
to 1{
n
2N
, where the higher
the value, the better the performance.
The ROC curve is a widely used way of representing the same
information; it plots the number of actual binders with respect to
the inactive molecules found in a docking run. It takes the
following expression:
1
nN
XN
k~2
Fa(k) Fi(k){Fi(k{1)½ , where the
subscript ‘‘i’’ stands for inactive molecule. It can be shown that the
area under the ROC curve is a linear transformation of the
AUAC, and more convenient since it ranges from 0 to 1. It follows
that they share the same information content and can be used
interchangeably.
The EFx is the measure of how many more binders are found
within a predefined ‘‘early recognition’’ fraction x of the ordered
list relative to a random distribution. Its expression can be recast in
this concise formula:
Fa txNsð Þ
xN
, where the t.s lower brackets
symbol stands for the greatest integer lower or equal to the
argument. It ranges from a minimum value of 0 to a maximum of
1
x
if x§ n
N
or
N
n
otherwise.
RIE is an early recognition metric that uses a decreasing
exponential weight as a function of rank. This exponential smoothing
should make RIE a more robust metric with respect to EF when a
small number of actives are considered. The counterpart of the 1x
quantity for EF is the a parameter of the exponential smoothing. The
discretized form of RIE is: a
2nNe{aza e{az2
PN{1
k~1
Fa(k)e
{
a
N
k
 
2nN 1{e{að Þ
and its range is
N 1{e
a
N
n
 
n 1{eað Þ ;
N 1{e{
a
N
n
 
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2
4
3
5.
Finally, the BEDROC metric was defined as a standardization
of the RIE so that it ranges from 0 to 1, and in fact it can be
expressed as:
RIE{RIEmin
RIEmax{RIEmin
. It appears clear from its definition
that it contains the same information as RIE, so they can be used
interchangeably.
Software and Hardware
The receptor and ligand preparations, the virtual ligand
screening simulations, and the energy evaluations were carried
out with ICM 3.7 (Molsoft L.L.C., La Jolla, CA). The statistical
analysis and figures of merit were calculated with purposely
developed in-house scripts in MATLAB v.7-R14 (MathWorks,
Natick, MA).
The hardware facilities used in the present study were a dual
Quad-Core AMD OpteronTM ‘‘Barcelona’’ workstation and a 42
Quad/Esa-Core 64-bit AMD OpteronTM ‘‘Istanbul/Shanghai’’
computer cluster.
Results and Discussion
I. The Dataset
The MRC-VLS simulations were carried out using two
independent datasets: DUD and the experimental Flexible
Pocketome. Thirty-six pharmaceutically relevant targets were
retrieved. For each of them, a series of conformations (Pocketome)
together with a set of known binders and bona fide non-binders
(DUD) were available. In particular, 2 to 30 conformers were
collected for each target (overall 457 high quality crystal
structures). The median intra family RMSD of the side chain’s
heavy atoms of the binding site was 1.6 A˚ while the median intra
family RMSD of the backbone was 1.0 A˚. Ligand sets encom-
passed from 8 to 365 known binders and from 155 to 15,560
decoys. Due to the filtering procedures introduced in the current
version of DUD [34], the average ratio between binders and
decoys was not fixed but varied slightly, with an average value of
0.023 (1:43), slightly lower than the original 0.028 (1:36). The set
includes 6 nuclear receptors and 29 enzymes comprising proteases,
hydrolases, kinases, etc. Details about MRC-VLS benchmark are
reported in Table 1, while a complete list of the PDB structures
included in the MRC-VLS test set is reported in the Supporting
Information (Table S1).
Here, we wanted to explore MRC-VLS capabilities against a set
of ligands compiled independently from the receptors. The choice
to combine already reported test sets for receptors and ligands
rather than compiling a new one from scratch reflected an
endorsement of the growing request in the field of VLS to adopt
accepted and shared standards [47]. To the best of our knowledge,
this is the most comprehensive test set where experimental protein
structures and known ligands are used together to explore the role
of MRC in a VLS study retrospectively. Finally, it should be
mentioned that the non-native protein conformer dataset,
compiled by Verdonk and coworkers [48] and extending the
approach that led to the Astex Diverse Set [49], could represent a
valid and appropriate alternative source of receptor variants for
MRC-VLS validation.
II. Binder Distribution in SRC-VLS runs
First, we focused on the assessment of SRC runs by plotting the
distribution of known binders against their relative rank (see
Figure 1A). The distribution displayed two maxima. The plot of an
ideal situation would present all binders located in the first
positions. However, in the rightmost part of Figure 1A, another
peak was observed. This showed that, in several cases, SRC-VLS
MRCs in Virtual Ligand Screening
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was not only unable to rank known binders in the top scoring
fraction but that these molecules ended up ranking lower than an
average decoy. This behavior was mainly due to the fact that some
receptor conformations could lodge certain ligands remarkably
well but could dump those which required a different binding site
rearrangement. For example, type I protein kinase inhibitor 1 (5,7
diphenylpyrrolo[2,3-d]pyrimidine, Figure 1B) ranked 6th when
screened using a conformation of the proto-oncogene tyrosine
protein kinase SRC (SRC_HUMAN) co-crystallized in complex
with a ligand very similar to 1 (PDBid: 1YOL, see also Figure S1A
in the Supporting Information). Conversely, 1 ranked only 5,118th
when docked at the inactive, DFG-out conformation of the same
protein when it is complexed with Imatinib (PDBid: 2OIQ). This
first example clearly shows the fundamental role of taking into
account several receptor conformations for relatively flexible
protein families (such as kinases). In a further case study, a selective
modulator (2) of the progesterone receptor (PRG_HUMAN) was
ranked 2nd when docked using the conformation solved in
complex with Asoprisnil (PDBid: 2OVH). The exceptionally high
score could be achieved since the N,N-dimethylanilino substituent
of 2 could almost perfectly fill an accessory pocket created by the
conformational rearrangement of Met909 side chain. Remarkably,
in this case too, 2 and the ligand co-crystallized in 2OVH were
structurally very similar (see also Figure S1B in the Supporting
Information). When using a conformer lacking the Met909-based
pocket (PDBid: 1ZUC), 2 could only be placed in position 920.
Table 1. The complete MRC-VLS test set.
TARGET Conformers Binders Decoys Total Ligands
Ratio
Binders/Non Binders Binders Chemotypes
ACE_HUMAN 7 46 996 1042 0.046 18
ACES_TORCA 21 99 3859 3958 0.025 18
ADA_BOVIN 13 23 927 950 0.024 8
ALDR_HUMAN 15 46 1796 1842 0.025 14
AMPC_COLI 16 21 786 807 0.026 6
ANDR_HUMAN 29 68 2848 2916 0.023 10
CDK2_HUMAN 30 47 2070 2117 0.022 32
COMT_RAT 3 11 468 479 0.023 2
DHFR_HUMAN 6 190 8350 8540 0.023 14
EGFR_HUMAN 6 365 15560 15925 0.023 40
ESR1_AG_HUMAN 4 63 2568 2631 0.024 10
ESR1_ANT_HUMAN 13 18 1058 1076 0.017 8
F10A_HUMAN 20 64 2092 2156 0.030 19
FGFR1_HUMAN 4 71 3462 3533 0.020 12
GCR_HUMAN 4 32 2585 2617 0.012 9
HMDH_HUMAN 9 25 1423 1448 0.017 4
HS9A_HUMAN 20 23 975 998 0.023 4
INHA_MYCTU 14 57 2707 2764 0.021 23
KITH_HHV11 19 22 891 913 0.025 7
MCR_HUMAN 11 13 636 649 0.020 2
MK14_MOUSE 19 137 6779 6916 0.020 20
NRAM_INBBE 11 49 1713 1762 0.028 7
PARP1_CHICK 6 31 1350 1381 0.023 7
PDE5A_HUMAN 11 26 1698 1724 0.015 22
PGH1_SHEEP 2 23 910 933 0.025 11
PGH2_MOUSE 2 212 7632 7844 0.027 44
PNPH_BOVIN 19 25 1036 1061 0.024 4
POL_HV1RT 18 34 1494 1528 0.022 17
PRGR_HUMAN 6 22 920 942 0.024 4
PUR3_COLI 3 8 155 163 0.051 5
PYGM_RABIT 20 52 2135 2187 0.024 10
RXRA_HUMAN 15 18 575 593 0.031 3
SRC_HUMAN 14 98 5679 5777 0.017 21
THRB_HUMAN 20 23 1148 1171 0.020 14
TRY1_BOVIN 19 9 718 727 0.012 7
VGFR2_HUMAN 8 48 2712 2760 0.017 31
doi:10.1371/journal.pone.0018845.t001
MRCs in Virtual Ligand Screening
PLoS ONE | www.plosone.org 4 May2011 | Volume 6 | Issue 5 | e18845
Aldose reductase (ALDR_HUMAN) provided another example of
how the binding site plasticity could affect VLS results. 3
(Tolrestat) ranked 1st when docked at the binding site of its
cognate receptor (PDBid: 1FZB). Due to a different rearrangement
of the Leu300 and Phe122 side chains (Figure 1D), 3 was ranked
915th in a VLS run carried out with a receptor conformation
obtained from the crystal structure of the enzyme in complex with
a different inhibitor (PDBid: 1T40, see also Figure S1C in the
Supporting Information). As expected, the analysis of the results
confirmed that true binders were ranked at the first positions,
when a suitable receptor conformation was used. In these cases,
SRC-VLS performed well in terms of early recognition.
Conversely, SRC-VLS could not identify true binders when
non-cognate receptor conformations (or similar) were used. In
these cases, the overall performance of true binders was even
worse than that of smaller decoys that could establish non-specific
interactions. This is in good agreement with previous reports on
the same topic [50,51]. Overall, SRC-VLS outperformed the
‘‘random picking’’ baseline (as expected); however it was unable to
guarantee a systematic ranking of true binders among the first hits.
True binders employed in this study were selected independently
from the receptor structures and annotated according to their
Figure 1. The role of induced fit in MRC VLS. A) Frequency distributions of SRC binders (blue area), MRC score binders (red area), and MRC rank
binders (green area) with respect to the relative rank they obtained in individual VLS runs. Two peaks emerge in the binders’ distribution: the highest
one, on the left, corresponds to the expected behavior where binders rank among the best positions, while the peak on the rightmost part of the
distribution corresponds to the opposite phenomenon. B) Inhibitor 1 at the binding site of SRC kinase. The structure that can accommodate the
ligand is reported in transparent green ribbons and the structure incompatible with the native binding mode in grey. The boundaries of the binding
site are highlighted by a semi-transparent white mesh. Inhibitor 1 and the interacting residues are reported explicitly in ball and stick representation
and labeled. Carbon atoms of inhibitor 1 are light yellow and carbon atoms of the binding site residues are light grey. The clashing residue Phe405
from the incompatible structure is reported explicitly in ball and stick representation with orange carbon atoms. The van der Waals volume of the
clashing Phe405 is highlighted by an orange mesh. Intermolecular hydrogen bonds are reported with dotted lines. C) Modulator 2 at the binding site
of Progesterone receptor. The structure that can accommodate the ligand is reported in transparent green ribbons and the structure incompatible
with the native binding mode in grey. The boundaries of the binding site are highlighted by a semi-transparent white mesh. Modulator 2 and the
binding site residues are reported explicitly in ball and stick representation and labeled. Carbon atoms of modulator 2 are light yellow and carbon
atoms of the binding site residues are light grey. The clashing residue Met909 from the incompatible structure is reported explicitly in ball and stick
representation with orange carbon atoms. The van der Waals volume of the clashing Met909 is highlighted by an orange mesh. D) Inhibitor 3 at the
binding site of aldose reductase. The structure that can accommodate the ligand is reported in transparent green ribbons and the structure
incompatible with the native binding mode in grey. The boundaries of the binding site are highlighted by a semi-transparent white mesh. Inhibitor 3
and the binding site residues are reported explicitly in ball and stick representation. Carbon atoms of inhibitor 3 are light yellow and carbon atoms of
the binding site residues are grey. Clashing residues Phe146 and Leu300 from the incompatible structure are reported explicitly in ball and stick
representation with orange carbon atoms. The van der Waals volumes of the clashing Phe123 and Leu301 are highlighted by orange meshes.
Figure 1B, 1C, and 1D were rendered with ICM3.7.
doi:10.1371/journal.pone.0018845.g001
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reported experimental activity. Unfortunately, a high experimen-
tal affinity does not automatically translate into favorable binding
scores in a docking or VLS experiment (and vice versa). Moreover,
overlooking receptor flexibility is not the only reason that can lead
to inaccurate predictions. Even in presence of a perfectly adapted
receptor structure, docking simulations can fail mainly because of
well known limitations and approximations introduced in
sampling and scoring, extensively reported and discussed else-
where [7–15]. Even in cross-docking, unexpected (if not
counterintuitive) results can be produced. For instance, a ligand
cannot be re-docked into its cognate receptor but can be
accurately lodged in another structure of the same target co-
crystallized with a different ligand [28]. Finally, it is worth to stress
that decoys employed here are bona fide non-binders, since their
lack of activity has not been proven experimentally. It would not
be unheard of that a decoy scored consistently well because it is
actually a binder [52].
The SRC-VLS performance depended on the specific target
and, to a lesser extent, on the figure of merit that was considered
[23,53]. For instance, using BEDROC figure of merit (blue plot in
Figure 2), individual docking runs performed on average four
times better than random picking.
III. Multiple Receptor Conformations Results
The first outcome of this study was a comparison between
MRC-VLS and SRC-VLS. For each target, all binders and
decoys collected in DUD were screened against all the
conformers of the receptor in the set. The MRC results were
generated, as described in the Methods section, according to the
MRC-score and MRC-rank combinations, and assessed using
different figures of merit. In particular, we selected AUAC, EF,
and BEDROC to reduce redundancy. For each of them, a
frequency distribution of the results obtained by MRC protocols
was compiled and the percentile in which these results fell was
reported. For example, six crystallographic structures are
available for the human progesterone receptor (PRGR_HU-
MAN). SRC-VLS runs carried out with each of them provided
the following results in terms of AUAC: 0.72, 0.70, 0.65, 0.62,
0.61, and 0.61. The AUAC corresponding to the MRC-score
protocol was 0.71, falling in the 85th percentile and outperform-
ing 5 SRC-VLS runs (out of 6). The AUAC corresponding to the
MRC-rank protocol was 0.84, outperforming all the SRC-VLS
runs and thus falling in the 100th percentile. We would like to
stress here that, for standard VLS runs (where experimental
information about possible binders and decoys are missing), the
conformation selection is a major issue because it can greatly
affect the VLS results, and also because it is very hard to establish
‘‘a priori’’ which conformer is able to provide the best results
[33]. Besides MRC-score and MRC-rank protocols, already
described in the Methods section, we explored several different
combination schemes, as briefly reported: i) using the second and
third best ranks obtained by a MRC docking campaign to reorder
ligands having the same best rank; ii) treating scores and ranks as
putative energy estimators, using them in a Boltzmann combi-
nation; iii) a second Boltzmann combination that included
molecular weights as a further ranking criterion; iv) testing the
overall combination of the ranks provided by all of the other
mentioned figures. None of these methods outperformed MRC-
score or MRC-rank.
III.A. AUAC. Table 2 and Figure 3A show the performance
of MRC-VLS protocol according to AUAC. In 9 out of 36 targets,
MRC-score performed equally well or better than any single
conformer (100th percentile). It was placed between the 99th and
the 90th percentile 4 times (i.e. for 4 targets), between the 90th and
the 75th percentile 6 times, and between the 75th and the 50th
percentile 10 times. For 5 targets, the MRC-score was placed
below the 50th percentile. On average, the MRC-score AUAC fell
in the 70th percentile or better, suggesting that multiple receptor
conformations enhanced the ability of this protocol to separate
binders from non-binders with respect to SRC-VLS. We then
analyzed in detail the runs that were below the 50th percentile. In
particular, two contrary scenarios were observed: i) for 3 targets
(PUR_ECOLI, PDE5A_HUMAN, and MCR_HUMAN), an
exceptionally high performance of SRC-VLS with all con-
formers was detected, and these results could not be further
improved by our MRC-VLS approach; ii) in contrast, for 2 targets
(ADA_BOVIN and HMDH_HUMAN), we observed very poor
performances (i.e. located below or barely above the threshold of
randomness), which could not be improved even using the MRC-
VLS protocol. ADA_BOVIN (i.e. adenosine deaminase) is a
Figure 2. Frequency distributions describing the performance of different protocols, as assessed by the BEDROCmetric, with a=20.
The red-bordered transparent grey rectangle represents the threshold of randomness. The blue area represents the frequency distribution of the
results for the individual runs (average), the red area represents the frequency distribution of the results for the MRC-score, and the green area
represents the frequency distribution of the results for the MRC-rank.
doi:10.1371/journal.pone.0018845.g002
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metalloenzyme involved in purine metabolism. It bears a very
peculiar network of interactions at the binding site, which revolves
around the coordination complex formed by a zinc ion, three
hystidine residues, and the inhibitor. Furthermore, the binding
pocket is quite large while the known ligands are relatively small.
For these reasons, ADA_BOVIN is widely recognized to be a very
complicated target for computational studies. As a matter of fact,
in the original DUD study by Huang and colleagues [35],
ADA_BOVIN was already reported as a target that did not
provide any significant separation between binders and non-
binders via a fully automated protocol. HMDH_HUMAN (i.e.
HMG-CoA reductase) is an interesting example of how noise
generated in individual runs can accumulate to compromise the
global performance of MRC-VLS. In particular, for several
receptor conformers, decoys systematically outranked true binders
and were assigned very high scores which, in turn, inflated their
final position in our MRC-VLS. Even though it is beyond the
purpose of the present study, it should be pointed out that,
exploiting the knowledge of an expert on the target biology, a
customized tuning of the binding pocket composition and of the
docking protocol parameters could significantly improve both the
SRC and MRC VLS performances [54].
In MRC-rank (Table 2), the results turned out to be slightly
better than in MRC-score. A few significant differences were
observed for the following targets: i) EGFR_HUMAN and
PRGR_HUMAN AUAC’s assessments were improved with
Table 2. SRC and MRC statistics in terms of AUAC.
TARGET
Number of
Conformers
Min SRC
AUAC
Max SRC
AUAC
Mean SRC
AUAC
MRC-score
AUAC
MRC-rank
AUAC
Ideal
AUAC
ACE_HUMAN 7 0.52 0.59 0.55 0.66 0.66 0.99
ACES_TORCA 21 0.43 0.73 0.55 0.67 0.63 0.99
ADA_BOVIN 13 0.20 0.39 0.28 0.15 0.17 0.99
ALDR_HUMAN 15 0.47 0.72 0.57 0.79 0.80 0.99
AMPC_COLI 16 0.28 0.59 0.45 0.47 0.44 0.98
ANDR_HUMAN 29 0.34 0.74 0.61 0.74 0.75 0.99
CDK2_HUMAN 30 0.52 0.81 0.65 0.82 0.81 0.99
COMT_RAT 3 0.51 0.58 0.54 0.54 0.55 0.99
DHFR_HUMAN 6 0.74 0.88 0.79 0.90 0.92 0.99
EGFR_HUMAN 6 0.41 0.65 0.51 0.54 0.65 0.99
ESR1_AG_HUMAN 4 0.71 0.82 0.76 0.82 0.82 0.99
ESR1_ANT_HUMAN 13 0.35 0.53 0.44 0.43 0.43 0.99
F10A_HUMAN 20 0.48 0.86 0.66 0.81 0.80 0.98
FGFR1_HUMAN 4 0.36 0.58 0.43 0.55 0.58 0.99
GCR_HUMAN 4 0.25 0.62 0.42 0.45 0.54 0.99
HMDH_HUMAN 9 0.60 0.77 0.65 0.58 0.61 0.99
HS9A_HUMAN 20 0.28 0.62 0.44 0.41 0.49 0.99
INHA_MYCTU 14 0.35 0.66 0.52 0.63 0.58 0.99
KITH_HHV11 19 0.40 0.75 0.6 0.74 0.72 0.99
MCR_HUMAN 11 0.80 0.87 0.85 0.82 0.84 0.99
MK14_MOUSE 19 0.28 0.70 0.47 0.61 0.62 0.99
NRAM_INBBE 11 0.79 0.90 0.85 0.88 0.86 0.99
PARP1_CHICK 6 0.67 0.79 0.73 0.83 0.83 0.99
PDE5A_HUMAN 11 0.65 0.84 0.77 0.77 0.77 0.99
PGH1_SHEEP 2 0.70 0.70 0.70 0.73 0.75 0.99
PGH2_MOUSE 2 0.58 0.75 0.67 0.71 0.69 0.99
PNPH_BOVIN 19 0.46 0.79 0.60 0.77 0.80 0.99
POL_HV1RT 17 0.46 0.68 0.61 0.72 0.76 0.99
PRGR_HUMAN 6 0.61 0.72 0.65 0.71 0.84 0.99
PUR3_COLI 3 0.80 0.88 0.85 0.85 0.94 0.99
PYGM_RABIT 20 0.21 0.44 0.32 0.22 0.26 0.99
RXRA_HUMAN 15 0.50 0.93 0.76 0.88 0.85 0.98
SRC_HUMAN 14 0.38 0.63 0.52 0.61 0.60 0.99
THRB_HUMAN 20 0.28 0.63 0.47 0.50 0.50 0.99
TRY1_BOVIN 19 0.33 0.89 0.69 0.76 0.79 0.99
VGFR2_HUMAN 8 0.45 0.62 0.55 0.70 0.73 0.99
doi:10.1371/journal.pone.0018845.t002
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respect to MRC-score; ii) the AUAC for GCR_HUMAN and
HS9A_HUMAN improved with respect to the median target
results in MRC-score; iii) PUR3_COLI could be moved from
below the 50th percentile in MRC-score (AUAC of 0.85) to the
100th percentile in MRC-rank (AUAC of 0.94). The one-tailed t-
student’s test for paired samples assessed that both MRC-score
and rank outperformed the average individual docking run with
high significance, p,1025.
III.B. EF. When the figure of merit considered was the EF1%
(Table 3 and Figure 3B), MRC-score was in the 100th percentile
for 9 targets. MRC-score results were placed between the 90th and
the 99th percentile 5 times, between the 75th and the 90th
percentile 5 times, and between the 50th and the 75th percentile 13
times. In only two examples, namely NRAM_INBEE and
DHFR_HUMAN, was the combined EF1% from MRC-score
placed below the 50th percentile. MRC-rank and MRC-score
provided very similar results, with MRC-score performing better
than MRC-rank when the instances that fell within the 90th
percentile were considered (14 for MRC-score and 11 for MRC-
rank). It should be pointed out that, for ADA_BOVIN and
COMT_RAT, both individual runs and MRC protocols
systematically failed to provide any enrichment at 1%. For these
two targets, MRC results were not included among those placed in
the 100th percentile since the fact that MRC performed equally
well with respect to the best SRC did not appear particularly
relevant.
EF1% is a stringent figure of merit and yet, in all but a very few
examples, MRC-VLS provided an early recognition that was
better than or equal to most SRC runs. The one-tailed t-student’s
test for paired samples for EF1% assessed that MRC-score and
MRC-rank protocols outperformed the average individual docking
run with a significance of p,0.0025 and p,0.001, respectively.
With an EF10% the improved performance of MRC-VLS was
indeed evident: MRC-score and MRC-rank were above the 90th
percentile for 16 and 15 targets, respectively. For 27 targets, both
MRC protocols were above the 75th percentile. The complete
results for EF10% are reported in the Supporting Information
(Table S2).
Comparing AUAC – a figure of merit for the overall
performance – and EF – a figure of merit for the early recognition
– we could confirm the general improvement in separating binders
from non-binders, and we could show that this improvement was
particularly marked in the topmost ranking fraction. This is
particularly relevant for VLS protocols, where early recognition of
true binders is a major achievement of this computational drug
discovery approach.
III.C. BEDROC. MRC-VLS combines an increased ability
to separate binders from non-binders with an improved propensity
toward early recognition. This ability can be concisely described
by adopting BEDROC as a figure of merit (see Methods).
According to the frequency distribution of the results (Table 4 and
Figure 3C), MRC-score outperformed or performed as well as the
best of the single rigid conformers 6 times, was between the 99th
and the 90th percentile 6 times, and between the 90th and 75th
percentile 6 times. In 16 targets, MRC-score produced results that
were between the 75th and the 50th percentile. PUR3_COLI and
MCR_HUMAN were the only targets whose MRC-score was
below the 50th percentile. MRC-rank was in the 100th percentile
12 times. It was between the 99th and the 90th percentile 3 times,
between the 90th and 75th percentile 11 times, and between the
50th and the 75th percentile 8 times. In two cases, namely
PDE5A_HUMAN and NRAM_INBBE, the MRC-rank was
below the 50th percentile despite being very close to the average
of SRC-VLS performance.
Figure 3. Distribution of the results of MRC-VLS runs according
to different figures of merit. Blue histograms represent MRC-score
results, red histograms represent MRC-rank results. The average SRC
performance is reported (green histograms) as a term of comparison. A)
Histograms representing the distribution of the results according to
AUAC. B) Histograms representing the distribution of the results
according to EF1%. C) Histograms representing the distribution of the
results according to BEDROC.
doi:10.1371/journal.pone.0018845.g003
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MRC-score (0.33) and rank (0.34) improved with respect to
SRC (0.25) when using BEDROC (see Figure 2). Of 36 targets,
MRC-score and MRC-rank outperformed SRC runs 33 and 32
times, respectively. The one-tailed t-student’s showed that the
significance of these results was p,1026.
MRC-rank outperformed MRC-score 23 times. Despite this
trend, which was also observed with other figures of merit, the
statistical significance of such a difference was not strong enough
to support the exclusive use of MRC-rank.
As it can be seen in Figure 1A, the MRC procedure tended to
enhance the extreme behaviors, leading to the depletion of the
intermediate region of affinity prediction. In fact, both significant
peaks in the MRC distributions, namely the one corresponding to
the best predicted binders and the one corresponding to the worst
ones, were larger than in the SRC derived distribution. Our ‘‘early
recognition’’ oriented approach benefits of the increment of the
first peak, leading to a better performance, and ignoring what
occurs in the other regions of the distribution.
A comparison between the MRC protocols and the so-called
consensus scoring is called for here. Consensus scoring is an
accepted approach which was reported to decrease the number of
false positives and to improve the hit rate [55,56]. It combines
multiple scoring schemes and it enriches those compounds that are
consistently placed in the first positions in each of them. Both
MRC and consensus scoring methods can improve the VLS
performance with respect to traditional SRC protocol. However,
Table 3. SRC and MRC statistics in terms of EF1%.
TARGET
Number of
Conformers
Min SRC
EF1%
Max SRC
EF1%
Mean SRC
EF1%
MRC-score
EF1%
MRC-rank
EF1% Ideal EF1%
ACE_HUMAN 7 6.5 21.7 15.2 23.9 23.9 39.1
ACES_TORCA 21 0 16.1 2.2 4.0 5.0 39.0
ADA_BOVIN 13 0 0 0 0 0 39.1
ALDR_HUMAN 15 0 30.7 17.9 34.6 30.8 38.4
AMPC_COLI 16 0 4.7 0.6 0 4.7 38.0
ANDR_HUMAN 29 2.9 23.5 14.7 25.0 22.0 42.6
CDK2_HUMAN 30 2.1 21.2 10.3 10.6 12.7 44.6
COMT_RAT 3 0 0 0 0 0 36.3
DHFR_HUMAN 6 13.7 33.6 20.3 14.2 20.5 44.7
EGFR_HUMAN 6 3 16.1 9.3 9.9 14.0 43.5
ESR1_AG_HUMAN 4 14.3 19.0 16.2 17.4 12.7 41.2
ESR1_ANT_HUMAN 13 0 22.2 12.4 16.6 11.1 55.5
F10A_HUMAN 20 0 25.0 7.9 15.6 9.3 32.8
FGFR1_HUMAN 4 2.8 7.0 4.5 2.8 9.8 49.2
GCR_HUMAN 4 0 25.0 7.3 25.0 25.0 81.2
HMDH_HUMAN 9 4 36.0 17.7 20.0 24.0 56.0
HS9A_HUMAN 20 0 21.7 6.7 0 17.4 39.1
INHA_MYCTU 14 0 8.7 2.0 5.2 1.7 47.3
KITH_HHV11 19 0 9.1 2.6 9.1 4.5 40.1
MCR_HUMAN 11 30.7 46.1 39.8 38.4 30.7 46.1
MK14_MOUSE 19 0 13.1 3.15 11.7 7.3 50.3
NRAM_INBBE 11 4.1 28.6 16.9 16.3 10.2 34.7
PARP1_CHICK 6 3.22 16.1 8.0 9.7 6.4 41.9
PDE5A_HUMAN 11 3.8 23.0 11.1 15.3 11.5 65.4
PGH1_SHEEP 2 13 17.4 15.2 17.4 13.0 39.1
PGH2_MOUSE 2 0.9 3.8 2.3 2.3 2.3 36.8
PNPH_BOVIN 19 0 16.0 5.0 4.0 16 40.0
POL_HV1RT 18 2.9 20.6 10.5 11.7 14.7 44.1
PRGR_HUMAN 6 13.6 27.2 22.7 27.2 27.2 40.9
PUR3_COLI 3 12.5 12.5 12.5 12.5 12.5 12.5
PYGM_RABIT 20 0 3.8 0.9 1.9 1.9 40.3
RXRA_HUMAN 15 0 22.2 5.9 11.1 5.5 27.7
SRC_HUMAN 14 1.0 15.3 8.4 11.2 10.2 58.1
THRB_HUMAN 20 0 13.0 5.0 4.3 4.3 47.82
TRY1_BOVIN 19 0 11.1 2.9 0 11.1 77.7
VGFR2_HUMAN 8 4.1 18.7 8.1 18.7 12.5 56.2
doi:10.1371/journal.pone.0018845.t003
MRCs in Virtual Ligand Screening
PLoS ONE | www.plosone.org 9 May2011 | Volume 6 | Issue 5 | e18845
although theoretically possible [57], retrospective studies have
clearly demonstrated that consensus scoring was not able to
outperform the best single scoring function [58]. Along the same
lines, MRC-VLS might be expected to display the same behavior,
achieving an overall accuracy that is between the average SRC-
VLS performance and the best one. However, in several
instances, MRC outperformed the best SRC run. Since the
MRC paradigm is based on the coexistence of different
conformers, which are mutually excluded in SRC runs, each
binder can ‘‘select’’ the most suitable conformation (according to
the induced fit paradigm), gaining an exceptionally good score. In
this way, MRC achieved higher levels of accuracy than SRC runs
and consensus scoring.
IV. Chemical Diversity in the Topmost Ranking
Compound Fraction
The MRC results were also analyzed in terms of chemotypes. A
VLS run should be able to enrich as many active compounds as
possible, preserving high chemical diversity [54]. In the DUD version
used herein, known binders underwent chemical-based cluster analysis
and were annotated accordingly. Each binder was converted into a
reduced graph and those sharing the same representation were
Table 4. SRC and MRC statistics in terms of BEDROC.
TARGET
Number of
Conformers
Min SRC
BEDROC
Max SRC
BEDROC
Mean SRC
BEDROC
MRC-score
BEDROC
MRC-rank
BEDROC Ideal BEDROC
ACE_HUMAN 7 0.23 0.37 0.31 0.45 0.44 1
ACES_TORCA 21 0.01 0.37 0.10 0.25 0.17 1
ADA_BOVIN 13 0 0.05 0.01 0.01 0.01 1
ALDR_HUMAN 15 0.04 0.47 0.3 0.66 0.66 1
AMPC_COLI 16 0.01 0.13 0.05 0.06 0.07 1
ANDR_HUMAN 29 0.12 0.45 0.32 0.45 0.45 1
CDK2_HUMAN 30 0.10 0.51 0.27 0.40 0.41 1
COMT_RAT 3 0.01 0.08 0.04 0.07 0.06 1
DHFR_HUMAN 6 0.38 0.71 0.48 0.55 0.64 1
EGFR_HUMAN 6 0.09 0.4 0.23 0.21 0.36 1
ESR1_AG_HUMAN 4 0.40 0.51 0.47 0.54 0.54 1
ESR1_ANT_HUMAN 13 0.01 0.33 0.22 0.30 0.28 1
F10A_HUMAN 20 0.05 0.59 0.26 0.53 0.38 1
FGFR1_HUMAN 4 0.08 0.25 0.14 0.17 0.22 1
GCR_HUMAN 4 0 0.30 0.11 0.27 0.28 1
HMDH_HUMAN 9 0.21 0.46 0.28 0.42 0.42 1
HS9A_HUMAN 20 0 0.37 0.11 0.05 0.23 1
INHA_MYCTU 14 0.01 0.20 0.09 0.19 0.12 1
KITH_HHV11 19 0.01 0.23 0.14 0.22 0.22 1
MCR_HUMAN 11 0.54 0.76 0.67 0.62 0.68 1
MK14_MOUSE 19 0.01 0.31 0.09 0.22 0.18 1
NRAM_INBBE 11 0.37 0.72 0.56 0.61 0.46 1
PARP1_CHICK 6 0.36 0.47 0.42 0.44 0.44 1
PDE5A_HUMAN 11 0.17 0.42 0.31 0.37 0.30 1
PGH1_SHEEP 2 0.25 0.31 0.28 0.30 0.33 1
PGH2_MOUSE 2 0.06 0.28 0.17 0.22 0.17 1
PNPH_BOVIN 19 0.03 0.49 0.2 0.31 0.39 1
POL_HV1RT 18 0.09 0.38 0.24 0.36 0.43 1
PRGR_HUMAN 6 0.24 0.49 0.39 0.53 0.54 1
PUR3_COLI 3 0.50 0.61 0.57 0.60 0.77 1
PYGM_RABIT 20 0 0.07 0.02 0.04 0.04 1
RXRA_HUMAN 15 0.11 0.62 0.35 0.49 0.33 1
SRC_HUMAN 14 0.04 0.27 0.17 0.26 0.22 1
THRB_HUMAN 20 0.03 0.27 0.18 0.24 0.27 1
TRY1_BOVIN 19 0.02 0.39 0.19 0.21 0.23 1
VGFR2_HUMAN 8 0.08 0.23 0.17 0.33 0.33 1
doi:10.1371/journal.pone.0018845.t004
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assigned to the same cluster. This specific partitioning scheme was
driven by chemical scaffolds and was very robust with respect to local
variants and decorations [59]. In the following, we report the case
study of FGFR1_HUMAN (i.e. the basic fibroblast growth factor
receptor 1) to fully illustrate this concept. For this target, there were 4
receptor conformations, 71 known binders, and 3462 non-binders.
The known binders were grouped in 12 chemotypes. Figure 4 reports
the chemotypes 1, 3, 4, and 9, which are those relevant to this case
study. Table 5 shows that each FGFR1_HUMAN conformer
enriched between 2 and 5 binders in the top 36 positions (top 1%).
In three cases (PDBid 1AGW, 1FGI, and 1FGK), these binders were
representative of chemotypes 1 and 3, and in one case (PDBid: 2FGI)
of chemotypes 4 and 9. MRC-score placed 2 binders representative of
chemotypes 3 and 9 in the top 1%. Finally, MRC-rank placed 7
binders representative of chemotypes 1, 3, 4, and 9 among the 36 best
ranked molecules. The improvement in terms of enrichment with
respect to SCR-VLS was absent in MRC-score and modest in MRC-
rank. However, when the same results were analyzed in terms of
diversity, MRC-score performed at the same level of the best SRC-
VLS, while MRC-rank doubled the number of SRC-VLS retrieved
scaffolds.
To investigate the ability of MRC-VLS protocols to preserve
diversity, the results were also analyzed considering only the
contribution of the best-ranked binder of each cluster to the
enrichment [54]. The other members of the same cluster were
labeled as non-binders and their contributions neglected. This
strategy greatly reduced the noise due to overrepresented scaffolds.
Figure 5 reports the complete distribution of the results
considering chemotypes only. When AUAC was used as a figure
of merit (Figure 5A), MRC-rank outperformed or performed as
well as any single conformer for 10 targets, while MRC-score was
in the 100th percentile 5 times. Altogether, MRC-rank and MRC-
score were above the 50th percentile in 23 and 25 instances,
respectively. For HMDH_HUMAN and ESR1_AG_HUMAN,
due to the exceptionally high performance of SRC-VLS, the MRC
results were in the 1st percentile even though calculated areas were
above 0.8. From a chemical diversity standpoint, the AUAC
results suggested that MRC-VLS was still beneficial, even though
improvement with respect to single conformers was reduced.
However, the scenario was completely different if we analyzed the
results in terms of EF1% (Figure 5B). In all but one case
(NRAM_INBEE, MRC-rank EF1% below the 50
th percentile),
MRC-VLS based approaches were above the 50th percentile. In
particular, MRC-rank was in the 100th percentile 16 times, while
MRC-score was in the 100th percentile 13 times. Dissimilar
Figure 4. Four different chemotypes enriched in the topmost fraction in single conformer and MRC-VLS studies on basic fibroblast
growth factor receptor 1.
doi:10.1371/journal.pone.0018845.g004
Table 5. Chemotype enrichment in different basic fibroblast
growth factor receptor 1 conformers.
PDBid
N. of Binders
in the
Topmost 1%
N. of Chemotypes
in the
Topmost 1%
Chemotypes
in the
Topmost 1%
1AGW 4 2 1–3
1FGI 2 2 1–3
1FGK 5 2 1–3
2FGI 2 2 4–9
MRC-score 2 2 3–9
MRC-rank 7 4 1–3–4–9
doi:10.1371/journal.pone.0018845.t005
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chemotypes were specifically recognized and assigned a good
score/rank by different conformers and, when the results were
combined together, the final EF1% was synergistically boosted. In
fact, different chemotypes reflect chemically different binders that
likely require different receptor conformations to be suitably
bound into the binding pocket. This is accounted for with our
MRC-VLS approach. The BEDROC results reflect the balanced
between the moderate improvement in overall separation and the
significant enhancement in early recognition that can be obtained
using MRC-VLS (see Figure 5C). In fact, MRC-rank provided
results that were above the 50th percentile in 33 targets. But it
outperformed or matched the results of the best SRC-VLS in only
7 targets. Similarly, MRC-score was placed over the 50th
percentile 34 times, but placed in the 100th percentile only 6
times. These results prove that our MRC-VLS approach increased
the number of active molecules among the top scorers (Figure 3B)
and, more importantly, enhanced the chemical diversity of true
binders. The latter represents the major novelty and added value
of our approach to hit identification campaigns.
Are co-crystals artificially inflating the beneficial role of
MRC?
Because DUD and the experimental Flexible Pocketome were
originally compiled independently, they partially overlap. Some of
the receptor conformers used here were actually extracted from
co-crystals bound to known binders in the set (see also Table S3 in
the Supporting Information). Since crystal structures of holo
proteins may retain a strong memory of their cognate ligands [31],
self-docking could artificially improve the final results. For this
reason, we decided to filter the ligand set by excluding from the
annotated binders: i) all the molecules co-crystallized with one of
the receptor variants and ii) all the binders belonging to the same
chemotype of a co-crystallized molecule (the chemotype of co-
crystallized molecules was defined according to the rules reported
in reference 34). Since highly populated chemotypes were more
likely to include a co-crystallized molecule, the total number of
binders and the diversity of the set were affected by the cognate
ligand filtering. On average, one third of the binders, but only one
fifth of the chemotypes, were excluded from the set. Three targets
(HS9A_HUMAN, KITH_HHV11, and MCR_HUMAN) had to
be excluded from the test set for the purpose of this analysis since
all of their binders were filtered out. In Figure 6, a complete
comparison of the BEDROC values is reported. A very small (and
somewhat expected) deterioration of the overall performance
could be observed. But, on average, the best single conformer,
MRC-score, and MRC-rank VLS provided for the filtered ligand
set are very similar to those of the non-filtered counterpart. The
average fluctuation was 0.03 for the best single conformers and
0.05 for the MRC approaches. Accordingly, the overall distribu-
tion of the results was very similar to the percentile analysis
reported in Figure 3 (see also Figure S2 in the Supporting
Information). The results quality dropped significantly for
GCR_HUMAN and HMDH_HUMAN only, implying that, in
these two targets, only co-crystals and closely related molecules
could be efficiently separated from non-binders. Interestingly, in
several cases, it was possible to detect a performance improvement
after co-crystallized ligands and their analogs were eliminated.
This depended on the noise generated by highly represented
chemotypes, which only provided a satisfactory performance in a
limited number of conformers, if at all. For example, the
acetylcholinesterase (ACES_TORCA) set of binders encompassed
the well-known inhibitor donepezil and twenty variants of the
same chemotype. While members of this cluster could be
separated quite well from non-binders in receptor conformers
Figure 5. Distribution of the results of MRC-VLS runs obtained
by considering only one representative binder for each
chemotype in the ligand set. Results are reported according to
different figures of merit. Blue histograms represent MRC-score results,
red histograms represent MRC-rank results. The average SRC perfor-
mance is reported (green histograms) as a term of comparison. A)
Histograms representing the distribution of the results according to
AUAC. B) Histograms representing the distribution of the results
according to EF1%. C) Histograms representing the distribution of the
results according to BEDROC.
doi:10.1371/journal.pone.0018845.g005
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displaying the right arrangement of the binding cavity, these 20
molecules were dumped at the rank bottom in all the other pocket
variants. Losing the huge amount of noise generated by donepezil
and its analogues more than compensated for their positive
contributions to the final ranking. If we consider Figure 1A, a
small reduction of the leftmost peak was compensated for by a
considerable reduction of the peak on the right. This, in turn,
translated into a better BEDROC score.
These findings are particularly relevant since they imply that
MRC-based approaches can statistically improve the quality of the
results in an actual VLS campaign, even in the absence of
structures specifically adapted to the molecules under examina-
tion. These results are in line with previously reported evidence
corroborating the idea that even a limited number of randomly
selected variants can outperform the traditional single rigid
receptor approach in cross docking and VLS [26–28,33]. In this
light, it appears safe to assume that crystal structures are not the
only valuable source of receptor conformations that can be used to
boost early recognition and chemical diversity in MRC-VLS. The
insights gained in this study can be extended to computer-
generated variants such as snapshots from molecular dynamics
[60] and, as was recently reported, homology models [61,62].
Attempts to Select an Optimal Subset of Receptor
Conformers
It has already been reported that the beneficial role of MRC in
VLS can be improved even further if an optimal subset of
receptor structures is selected from among the available
conformers [33,63,64]. However, it is quite difficult to define
such a subset in advance. In our retrospective study, we noticed a
perfect correspondence between the runs that yielded positive
ICM docking scores for all the molecules in the dataset and those
that presented an EF1%,1, i.e. those performing worse than a
random selection. We were led by this observation to believe that
these runs did not contribute any useful information, and we
therefore performed the tests again after excluding them. The
first consequence was to eliminate three targets from the study,
namely ADA_BOVIN, COMT_RAT and PGH2_MOUSE. As a
matter of fact, the available conformations of the first two targets
were characterized by ‘‘bad runs’’ only, i.e. the yielding of
positive scores only. According to our hypothesis, the relative
ranking provided by the docking runs should have been of very
low significance. Indeed, that was the case. In ADA_BOVIN,
each individual run performed much worse than the random
selection, while the discriminating ability in COMT_RAT was
fairly similar to that of the random selection. In these cases,
consistent with the ‘‘garbage in, garbage out’’ byword, the MRC
procedure could not distil any useful information from the
individual runs. Only two conformations were available for the
PGH2 MOUSE target and, of these, one had to be filtered out.
In this case, there was no sense applying the MRC method.
However, thanks to the filtering protocol, the most capable
conformation could be identified (BEDROC = 0.28 versus 0.06 of
the discarded one).
If we now consider the remaining targets, MRC-score and
MRC-rank with pre-filtering outperformed the corresponding
versions without the filtering protocol with a statistical significance
(assessed via the one-tailed t-test for paired samples) p,0.07 for
every figure of merit considered in this work. The BEDROC
measure, which takes into account both early recognition and
overall performance, particularly benefited from this protocol
because the corresponding statistical significance was p,0.005
and p,0.0001 for MRC-score and MRC-rank, respectively. Even
more impressively, in slightly more than 40% of targets, this
protocol allowed MRC-rank to perform better than the best of the
individual runs. The results for MRC-rank performance after
filtering out receptor structures that yield only positive ICM
docking scores are reported in Figure 6.
In summary, filtering out those individual runs that provided
only positive ICM docking scores seems to be an easy way of
Figure 6. Frequency distributions describing the performance of different protocols, as assessed by the BEDROCmetric, with a=20.
The red bordered transparent grey rectangle represents the threshold of randomness. The indigo area represents the frequency distribution of the
results for the individual runs (average), the blue area represents the frequency distribution of the results for the best single performing conformer
from each ensemble, the red area represents the frequency distribution of the results for the MRC-rank including all available conformer for each
ensemble, and the green area represents the frequency distribution of the results for the MRC-rank, dropping the conformers that provide a positive
score for each ligand.
doi:10.1371/journal.pone.0018845.g006
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removing noise from the calculation and best exploiting the MRC
procedure.
Conclusions
In this work, the role of MRC in VLS has been systematically
analyzed on a diverse and challenging test set, and several
protocols for exploiting MRC availability are suggested. Before
testing our protocols, we first established a baseline to assess the
performance of the docking engine. We found it to be appreciable
and in line with the literature. This preliminary step was necessary
to understand whether or not our protocol provided a real
improvement. The protocols we suggested, namely the MRC-
score and the MRC-rank, statistically outperform the average
single conformation run, and this is particularly true as far as the
topmost ranking fraction is concerned. This latter is the most
relevant fraction when VLS is considered not just as a standalone
exercise, but as part of a drug discovery project. It is not entirely
clear whether MRC-rank should be preferred to MRC-score, even
if the results reported here seem to point in that direction. From a
chemical diversity perspective, we proved that MRC improved not
only the number of active molecules enriched in the top fraction,
but also the variety of scaffolds. Again, this is crucial for real life
drug discovery. Furthermore, we proved that the quality of the
results does not depend on a bias introduced by co-crystals. Even
with co-crystals excluded from the analysis, MRC still outperforms
SRC-VLS. On the other hand, it is reasonable to assume that even
more structurally diverse ensembles would increase the likelihood
of discovering truly novel scaffolds.
We observed that conformations that yield only positive scores
in the docking phase can safely be excluded, leading to a
significant improvement in the final results. This is a simple yet
practical criterion for making a preliminary selection of the
conformers whenever a set of known binders and decoys is
available. Each of the figures of merit considered in this study has
its own peculiarities and privileged domains of application. In a
real VLS scenario, where ‘‘early recognition’’ is often crucial,
enrichment factors and BEDROC seem to be the most
appropriate to evaluate performance.
Finally, we note that MRC strategies significantly increase the
computational burden, since the calculation time scales linearly
with the number of conformers. However, docking engines
purposely developed to integrate MRC in standard protocols
were recently reported and will help limit the impact of this issue
[32,65,66].
Supporting Information
Figure S1 Structural comparison with cognate ligands A)
Inhibitor 1 at the binding site of SRC kinase (PDBid 1YOL).
Inhibitor 1 and the binding site residues are reported explicitly in
ball and stick representation. Inhibitor 1 alpha carbons are colored
green. As a term of comparison, the cognate ligand CGP77675 is
reported explicitly in ball and stick representation with dull grey
carbon atoms. The boundaries of the binding site are highlighted
by a semi-transparent white mesh. Intermolecular hydrogen bonds
are reported with dotted lines. B) Modulator 2 at the binding site
of Progesterone receptor (PDBid:2OVH). Modulator 2 and the
binding site residues are reported explicitly in ball and stick
representation. Modulator 2 alpha carbons are colored green. As a
term of comparison, the cognate ligand Asoprisnil is reported
explicitly in ball and stick representation with dull grey carbon
atoms. The boundaries of the binding site are highlighted by a
semi-transparent white mesh. C) Tolrestat (3) at the binding site of
aldose reductase (PDBid: 2FZB). Tolrestat and the binding site
residues are reported explicitly in ball and stick representation.
Tolrestat alpha carbons are colored green. As a term of
comparison, the cognate ligand IDD552 is reported explicitly in
ball and stick representation with dull grey carbon atoms. The
boundaries of the binding site are highlighted by a semi-
transparent white mesh.
(PDF)
Figure S2 Performance comparison of different protocols, as
assessed by the BEDROC metric, with a= 20, including and
excluding co-crystallized ligands. For each target, six histograms
are reported: best single conformer, all ligands – red; best single
conformer, no co-crystals – yellow; MRC score, all ligands – blue;
MRC score, no co-crystals – white; MRC rank, all ligands – green;
MRC score, no co-crystals – orange.
(PDF)
Table S1 List of PDB structures included in the test set.
(PDF)
Table S2 Distribution of the results expressed by EF10%.
(PDF)
Table S3 Known binders and co-crystallized ligands overlap.
(PDF)
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